Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Therapy save search
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ITCI 4 d | $73.96 -0.78% -0.78% 830K
|
Health Technology
|
| O: 14.75%
H: 12.75%
C: 6.04%
positive topline therapy results study
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.24 0.0% 6.9M
|
Health Technology
|
| O: 2.92%
H: 3.41%
C: 2.27%
ocu400 approval positive for therapy
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.32 7.26% 6.77% 30K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Published: 2024-04-02 (Crawled : 12:30) - prnewswire.com
GNPX | $2.32 7.26% 6.77% 30K
|
Health Technology
|
| O: -5.72%
H: 7.14%
C: 1.43%
oncoprex positive system preclinical therapy
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-03-06 (Crawled : 13:30) - prnewswire.com
GNPX | $2.32 7.26% 6.77% 30K
|
Health Technology
|
| O: 24.27%
H: 5.66%
C: -14.45%
reqorsa lung positive treatment system preclinical meeting therapy
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
BCDA P | $0.3678 -2.56% 80K
|
Health Technology
|
| O: 0.03%
H: 1.72%
C: -21.53%
biomarker positive cell cardiamp heart therapy results
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
LEGN | News | $47.42 0.77% 0.76% 1.8M
|
Health Technology
|
| O: 2.07%
H: 5.02%
C: 4.92%
carvykti chmp biotech positive treatment therapy
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Published: 2024-02-23 (Crawled : 12:30) - prnewswire.com
ATNM | $6.96 -2.93% -1.14% 190K
|
Health Technology
|
| O: 4.45%
H: 1.85%
C: -2.56%
tp53 astct positive leukemia trial therapy
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.25%
H: 2.95%
C: 2.88%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.43%
H: 1.06%
C: -0.05%
qalsody first chmp genetic positive treat therapy
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
Published: 2024-02-12 (Crawled : 21:00) - globenewswire.com
RMD | $184.22 2.15% 0.0% 1.2M
|
Health Technology
|
| O: -1.57%
H: 1.1%
C: -0.27%
positive therapy
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.71%
H: 0.48%
C: -0.52%
chmp positive cell therapy
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
genetic association positive research meeting trial therapy
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
SELB 4 | $0.8812 -8.0% 2.12% 0
|
Health Technology
| Email alert
Add to watchlist
candidate mrna positive cell therapeutics therapy study
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2023-12-15 (Crawled : 21:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.64%
H: 0.21%
C: -1.79%
hyqvia chmp positive therapy
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
Published: 2023-12-15 (Crawled : 14:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.31%
H: 0.98%
C: -3.58%
skyclarys rare first disease chmp positive treat neurodegenerative therapy
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
first disease breast cancer treatment therapy show
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Published: 2023-12-08 (Crawled : 17:00) - globenewswire.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
first disease breast cancer treatment therapy show
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
PROK | $2.545 -6.43% -6.88% 1.1M
|
|
| O: 13.75%
H: 2.75%
C: -16.48%
rmcl-002 react renal positive cell trial therapy diabetic
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
Published: 2023-11-10 (Crawled : 13:00) - prnewswire.com
BPMC | $92.32 1.89% 1.85% 790K
|
Health Technology
|
| O: 1.15%
H: 2.66%
C: 1.62%
ayvakyt chmp positive therapy
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients
Published: 2023-11-09 (Crawled : 15:30) - biospace.com/
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: 4.94%
H: 4.7%
C: 0.41%
pds0101 biotech cancer trial therapy
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.